Clinical Trials
28 trialsNCT05519085 2026-05-27
SUCCESSOR-1
Celgene
Phase 3 Recruiting
NCT07138209 2026-05-22
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
Qilu Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT06615479 2026-05-13
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3 Recruiting
NCT07579234 2026-05-12
A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma
Shandong New Time Pharmaceutical Co., LTD
Phase 3 Recruiting
NCT05455320 2026-04-13
MonumenTAL-3
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT05572515 2026-04-13
MajesTEC-9
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT05552976 2026-04-01
SUCCESSOR-2
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT03539744 2025-06-19
A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
AbbVie
Phase 3 Active not recruiting
NCT03765541 2025-04-10
DEXAML-03
University Hospital, Toulouse
Phase 3 Terminated
NCT06561854 2024-12-18
FREEDOM
Assistance Publique - Hôpitaux de Paris
Phase 3 Recruiting
NCT03836014 2024-12-06
CONFIRM
Assistance Publique - Hôpitaux de Paris
Phase 3 Active not recruiting
NCT03110562 2024-08-21
BOSTON
Karyopharm Therapeutics Inc
Phase 3 Completed
NCT03859427 2024-08-13
ARROW2
Amgen
Phase 3 Completed
NCT06232707 2024-05-31
ALUMMINATE
Celgene
Phase 3 Withdrawn
NCT03651128 2022-12-15
KarMMa-3
Celgene
Phase 3 Active not recruiting
NCT03029234 2022-05-25
Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma
Amgen
Phase 3 Completed
NCT05236621 2022-02-11
A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Qilu Pharmaceutical Co., Ltd.
Phase 3 Unknown
NCT01712789 2022-01-10
STRATUS
Celgene
Phase 3 Completed
NCT00256776 2021-10-18
MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation
European Society for Blood and Marrow Transplantation
Phase 3 Terminated
NCT01023308 2020-03-17
PANORAMA-1
Novartis
Phase 3 Completed
NCT01470131 2018-12-19
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
AB Science
Phase 3 Terminated
NCT01311687 2018-10-24
NIMBUS
Celgene
Phase 3 Completed
NCT03623087 2018-08-14
SIMPLE Chemotherapy for NK Lymphoma/Leukaemia
The University of Hong Kong
Phase 3 Unknown
NCT00056160 2017-10-19
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Celgene
Phase 3 Completed
NCT01449344 2017-03-07
(R-HAD)
European Mantle Cell Lymphoma Network
Phase 3 Unknown
NCT01266811 2013-01-28
A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Centocor, Inc.
Phase 3 Withdrawn
NCT00478777 2011-11-03
A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma
Celgene
Phase 3 Completed
NCT00179647 2010-03-16
Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma
Celgene
Phase 3 Completed